Selinexor and Radiation Therapy in Pediatric Glioma and High-Grade Glioma

What is the Purpose of this Study?

The purpose of this study is to evaluate the effectiveness of an experimental drug called selinexor in children and young adults who have been diagnosed with high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG). A glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high-risk (or high-grade) when it is growing and spreading quickly. DIPG is a subtype of HGG that grows in the pons (a part of the brainstem that controls functions like breathing, swallowing, speaking, and eye movements). The study aims to find the highest dose of selinexor that can be safely given with radiation therapy (Part 1 of the study, which has been completed). Researchers also want to determine the effects that selinexor has on people with HGG, DMG or DIPG and whether it is a beneficial treatment for the patient’s tumor (Part 2). In Part 2, participants will receive the maximum tolerated dose of selinexor. If the patient experiences negative side effects, the dose may be decreased.


Eligibility

  • * PRE ENROLLMENT: Patients must be =\< 25 years of age at the time of enrollment on APEC14B1 part A cnetral nervous system (CNS)/high grade glioma (HGG) pre-enrollment eligibility screening
  • * Please note:
Show more

Where can I participate?

CS Cancer at Cedars-Sinai Medical Center : Emilie Douine-Barthelemy

More about this Clinical Trial

What is the full name of this clinical trial?

ACNS1821 A Phase 1/2 Trial of Selinexor and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma and High-Grade Glioma

Study Details
Disease Type/Condition

Brain and Nervous System

Principal Investigator

Majlessipour, Fataneh

Co-Investigators

Leo Mascarenhas, Nicole Baca

Age Group

Both

Phase

I/II

IRB Number

STUDY00003850

ClinicalTrials.gov ID

NCT05099003

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Name

Emilie Douine-Barthelemy

Email
emilie.douine-barthelemy@cshs.org
Study Detail
Disease Type/Condition

Brain and Nervous System

Principal Investigator

Majlessipour, Fataneh

Age Group

Both

Phase

I/II

IRB Number

ACNS1821

ClinicalTrials.gov ID

NCT05099003

Key Eligibility
ClinicalTrials.gov

Contact
Name

Emilie Douine-Barthelemy

Email
emilie.douine-barthelemy@cshs.org